JADE BIOSCIENCES INCJBIO
ASignal's systematic analysis rates JBIO as Neutral.
Reflects the latest available analysis · analyzed Sep 17, 2026
The case on JBIO
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong financial health score (0.9)
- Near-zero debt with debt-to-equity of 0.00x
- High cash reserves ($461.20M)
- High liquidity (current ratio 14.93x)
- Oversold RSI (20.03) suggesting potential reversal
- Negative MACD and weakening momentum
- Negative operating cash flow (-$123.51M)
- Lack of profitability (0.00% margins)
- No free cash flow data available
- Limited retail sentiment (0 Reddit mentions)
- Valuation metrics negative or undefined (e.g., forward P/E -6.25x, EV/EBITDA -3.92x)
See the full verdict on JBIO
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes JBIO
Most investors never get a second opinion, let alone several. ASignal runs JBIO past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.